Healthcare Industry News: antiviral
News Release - December 6, 2017
Viriom Announces New Director AppointmentSAN DIEGO, Dec. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Viriom Inc. is pleased to announce the appointment of Augustine Lawlor as Director of Viriom. Mr. Lawlor brings to Viriom his extensive operating experience in strategic business development, finance, management of mergers and acquisitions, as well as general management in the biotechnology industry.
Mr. Lawlor is the Managing Partner of HealthCare Ventures LLC, where he has worked for over 17 years, and a board member of numerous life science companies. Before joining HealthCare Ventures, Mr. Lawlor served as Vice President of Corporate Development & Chief Financial Officer, and later as Chief Operating Officer, at LeukoSite, Inc. Prior to that, Mr. Lawlor was the Chief Financial Officer and Vice President of Corporate Development at Alpha-Beta Technology, and held similar positions at BioSurface Technology and Armstrong Pharmaceuticals, Inc. Earlier, he was working for KPMG as a management consultant. Mr. Lawlor received his Master's degree in Public and Private Management from Yale University.
"Mr. Lawlor's expertise in the intricate workings of the biotechnology industry and his knowledge of the most efficient results-driven business development strategies will help accelerate Viriom's efforts in developing a truly global antiviral platform," said Nikolay Savchuk, PhD, Chairman of the Viriom Board. "We are excited to work together on offering novel and affordable therapies against life-threatening infections including HIV and hepatitis B."
"The main reason why millions of people still live with HIV and HBV, and thousands keep getting infected every day, is the unaffordability of modern treatments," commented Augustine Lawlor. "Viriom offers a solution: antiviral treatments that are not only effective, but also affordable, and can be used for both treatment and prophylaxis. Viriom's cost-effective approach to drug development at scale can bring the much-needed solution to HIV and HBV problems around the globe, and I am delighted to be a part of Viriom's team and to contribute to advancing its novel therapies."
Viriom Inc. is a late-stage biotech company developing, manufacturing and distributing novel and affordable therapies against life-threatening infections such as HIV and HBV. Viriom holds exclusive worldwide rights from F. Hoffmann-La Roche for VM1500, which it is presently developing as an oral AIDS treatment (Elsulfavirine) for active HIV infections; and as innovative longer-acting formulations of Elsulfavirine for PrEP and PEP in high-risk patient populations. Viriom is also developing a proprietary therapeutic for chronic HBV infections. Viriom believes its drug candidates are capable of achieving breakthroughs in treatment and prevention of HIV and chronic HBV infections in both developing and developed countries. For more information, please visit www.viriom.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.